Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 9/20 | 0.50 |
| ▸ | BCL6 | P41182 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.44 |
| ▸ | JAK2 | O60674 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 3/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | INSR | P06213 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15492039 | 0.84 | AURKA (0.68) | KMT2AAURKABCL6AURKBJAK2 | |
| SCHEMBL30833632 | 0.84 | BCL6 (0.50) | KMT2AMEN1GAABCL6ALDH1A1 | |
| SCHEMBL3340093 | 0.84 | BCL6 (0.50) | KMT2AMEN1GAABCL6ALDH1A1 | |
| SCHEMBL30833802 | 0.82 | IGF1R (0.55) | KMT2AMEN1GAAALDH1A1MAPK8 | |
| SCHEMBL3864935 | 0.82 | AURKA (0.50) | KMT2AAURKAAURKBJAK2ALDH1A1 | |
| SCHEMBL24260666 | 0.82 | IGF1R (0.55) | KMT2AMEN1GAAALDH1A1MAPK8 | |
| SCHEMBL30833794 | 0.82 | GAA (0.42) | KMT2AMEN1GAAAURKAALDH1A1 | |
| SCHEMBL22807434 | 0.82 | EGFR (0.42) | KMT2AMEN1GAAALDH1A1IGF1R | |
| SCHEMBL22828247 | 0.82 | GAA (0.42) | KMT2AMEN1GAAAURKAALDH1A1 | |
| SCHEMBL29549370 | 0.82 | EGFR (0.42) | KMT2AMEN1GAAALDH1A1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014170421-A1 | SERINE/THREONINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-23 | — | — | WO | disclosed |
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120172384-A1 | HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120172384-A1 | HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120172384-A1 | HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-20120040955-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | CELLZOME LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| WO-2011029807-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-03-17 | — | — | WO | disclosed |
| WO-2010146133-A1 | HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010142766-A2 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010118986-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | CELLZOME LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
| WO-2009127642-A2 | USE OF LRRK2 INHIBITORS FOR NEURODEGENERATIVE DISEASES | CELLZOME LIMITED (GB) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | ZAP70, LCK, DPY30 | KMT2A 2423/4885MEN1 4303/4885GAA 2193/4885 |
| US-20120040955-A1 | FLUORO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | KMT2A 1056/4885MEN1 3289/4885GAA 3876/4885 |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | ZAP70, SYK, LCK | KMT2A 280/4885MEN1 4489/4885GAA 2048/4885 |
| US-20120172384-A1 | HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS | ZAP70, JAK3, JAK2 | KMT2A 807/4885MEN1 2286/4885GAA 2803/4885 |
| US-20120172385-A1 | ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS | JAK3, JAK1, JAK2 | KMT2A 1909/4885MEN1 4276/4885GAA 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.